OKUR · OnKure Therapeutics, Inc.
$3.94
+0.01 (+0.25%)
At close · Aug 21
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had determined that substantial doubt about the Company's ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following completion of the 2026 Private Placement (see Note 9), management believes the Company's cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these condensed consolidated financial statements and as such substantial doubt has been alleviated.”View the 10-Q filed Aug 4, 2026
Market Cap
$159.56M
Shares
40.50M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2024
Net Income
-$59.52M
-13%
FY2025
Diluted EPS
-$4.40
+71.2%
FY2025
Operating Cash Flow
-$51.83M
-1.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | $0 | — | — | — | — | |
| $3.44M | $3.43M | $1.71M | $1.62M | — | — | — | |
| $46.95M | $48.26M | $43.8M | $32.12M | $37.71M | $28.17M | $15.94M | |
| $15.19M | $14.69M | $10.59M | $4.82M | $16.14M | $11.65M | $3.61M | |
| $433K | $447K | $459K | $417K | $88K | $50K | $37K | |
| $62.14M | $62.95M | $54.39M | $36.93M | $53.85M | $39.82M | $19.55M | |
| -$62.14M | -$62.95M | -$54.39M | -$36.93M | -$53.85M | -$39.82M | -$19.55M | |
| -$61.13M | -$62.5M | -$53.93M | -$36.52M | -$53.76M | -$39.77M | -$19.52M | |
| $4.56M | — | — | $5.67M | $1.89M | $48K | — | |
| — | — | — | -$77.39M | -$51.96M | -$39.77M | -$19.47M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$58.71M | -$59.52M | -$52.67M | -$35.31M | -$51.96M | -$39.77M | -$19.47M | |
| — | — | — | -$77.34M | -$52.03M | -$39.74M | -$19.47M | |
| USD/shares | — | -$4.40 | -$15.28 | -$124.41 | -$21.20 | -$21.90 | -$96.00 |
| USD/shares | — | -$4.40 | -$15.28 | -$124.41 | -$21.20 | -$21.90 | -$96.00 |
| shares | — | 13.52M | 3.45M | 283.82K | 2.45M | 1.81M | 202.82K |
| shares | — | 13.52M | 3.45M | 283.82K | 2.45M | 1.81M | 202.82K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.19×
EV/EBIT
—
Peer median 11.20×
P/E (TTM)
—
Peer median 9.28×
Peer medians compare against the 305 similar-size Biotechnology companies (of 545 listed).
Key facts
CIK
1637715
CUSIP
68277Q105
13F (30d)
76 filings
74 filers
Visit website
Investor relations